ACCOUNTS - Final Accounts


Caseware UK (AP4) 2018.0.111 2018.0.111 2018-05-312018-05-31The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.truefalseNo description of principal activityfalse2017-06-01 08905301 2017-06-01 2018-05-31 08905301 2018-05-31 08905301 2017-05-31 08905301 c:Director1 2017-06-01 2018-05-31 08905301 d:CurrentFinancialInstruments 2018-05-31 08905301 d:CurrentFinancialInstruments 2017-05-31 08905301 d:Non-currentFinancialInstruments 2018-05-31 08905301 d:Non-currentFinancialInstruments 2017-05-31 08905301 d:CurrentFinancialInstruments d:WithinOneYear 2018-05-31 08905301 d:CurrentFinancialInstruments d:WithinOneYear 2017-05-31 08905301 d:ShareCapital 2018-05-31 08905301 d:ShareCapital 2017-05-31 08905301 d:SharePremium 2018-05-31 08905301 d:SharePremium 2017-05-31 08905301 d:RetainedEarningsAccumulatedLosses 2018-05-31 08905301 d:RetainedEarningsAccumulatedLosses 2017-05-31 08905301 c:FRS102 2017-06-01 2018-05-31 08905301 c:AuditExempt-NoAccountantsReport 2017-06-01 2018-05-31 08905301 c:FullAccounts 2017-06-01 2018-05-31 08905301 c:PrivateLimitedCompanyLtd 2017-06-01 2018-05-31 iso4217:GBP

Registered number: 08905301









BIOEMULOUS LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 31 MAY 2018

 
BIOEMULOUS LIMITED
REGISTERED NUMBER: 08905301

BALANCE SHEET
AS AT 31 MAY 2018

2018
2017
Note
£
£

Fixed assets
  

Investments
 4 
13,500
13,500

  
13,500
13,500

Current assets
  

Debtors: amounts falling due after more than one year
 5 
246,381
257,351

Cash at bank and in hand
  
46,700
3,827

  
293,081
261,178

Creditors: amounts falling due within one year
 6 
(1,662)
(800)

Net current assets
  
 
 
291,419
 
 
260,378

Total assets less current liabilities
  
304,919
273,878

  

Net assets
  
304,919
273,878

Page 1

 
BIOEMULOUS LIMITED
REGISTERED NUMBER: 08905301
    
BALANCE SHEET (CONTINUED)
AS AT 31 MAY 2018

2018
2017
Note
£
£

Capital and reserves
  

Called up share capital 
  
15,424
15,364

Share premium account
  
292,616
260,678

Profit and loss account
  
(3,121)
(2,164)

  
304,919
273,878


The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of income and retained earnings in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 27 February 2019.




Alan Charles Bashforth
Director

The notes on pages 3 to 4 form part of these financial statements.

Page 2

 
BIOEMULOUS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2018

1.


General information

Bioemulous Limited is a private limited company limited by share capital. The company is registered in England and Wales, company number 08905301. The company's registered office address is 1 The Green Richmond Surrey TW9 1PL.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Section 1A of Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006.

The following principal accounting policies have been applied:

 
2.2

Valuation of investments

Investments in subsidiaries are measured at cost less accumulated impairment.

Investments in unlisted Company shares, whose market value can be reliably determined, are remeasured to market value at each balance sheet date. Gains and losses on remeasurement are recognised in the Statement of income and retained earnings for the period. Where market value cannot be reliably determined, such investments are stated at historic cost less impairment.

Investments in listed company shares are remeasured to market value at each Balance sheet date. Gains and losses on remeasurement are recognised in profit or loss for the period.

 
2.3

Associates and joint ventures

Associates and Joint Ventures are held at cost less impairment.

 
2.4

Creditors

Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees

The Company has no employees other than the directors, who did not receive any remuneration (2017 - £NIL).

The average monthly number of employees, including directors, during the year was 0 (2017 - 0).

Page 3

 
BIOEMULOUS LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MAY 2018

4.


Fixed asset investments





Investments in associates

£



Cost or valuation


At 1 June 2017
13,500



At 31 May 2018
13,500





5.


Debtors


Due after more than one year

Amounts owed by group undertakings
246,381
257,351

246,381
257,351



6.


Creditors: Amounts falling due within one year

2018
2017
£
£

Accruals and deferred income
1,662
800

1,662
800


 
Page 4